Core Viewpoint - Mamei Biological (603983.SH) plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and overseas financing capabilities, aiming to improve its overall competitiveness and accelerate its international business strategy [1] Group 1 - The company aims to strengthen its capital and financing capabilities through the issuance of H-shares [1] - The listing on the Hong Kong Stock Exchange is part of the company's overall development strategy and operational needs [1] - The initiative is expected to enhance the company's comprehensive competitiveness [1]

（文章来源：第一财经） 丸美生物晚间公告，公司拟发行H股股票并申请在香港联交所主板挂牌上市。 ...

Market Overview - The cosmetics sector increased by 0.24% on November 12, with Jiaheng Jiahua leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Individual Stock Performance - Jiaheng Jiahua (300955) closed at 39.79, up 6.82% with a trading volume of 110,800 shares and a turnover of 429 million yuan [1] - Huaye Fragrance (300886) closed at 30.72, up 1.96% with a trading volume of 32,700 shares and a turnover of 99.64 million yuan [1] - Shanghai Jahwa (600315) closed at 24.60, up 0.78% with a trading volume of 62,900 shares and a turnover of 15.5 million yuan [1] - Other notable stocks include Bawei Co. (920123) at 18.31, up 0.72%, and Kesheng Co. (300856) at 14.00, up 0.50% [1] Capital Flow Analysis - The cosmetics sector experienced a net outflow of 66.86 million yuan from institutional investors, while retail investors saw a net inflow of 2.95 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are entering the market [2] Detailed Capital Flow by Stock - Qing Song Co. (300132) had a net inflow of 5.60 million yuan from institutional investors, while it faced a net outflow of 7.23 million yuan from speculative funds [3] - Shanghai Jahwa (600315) saw a net inflow of 5.19 million yuan from institutional investors but a net outflow of 8.56 million yuan from retail investors [3] - Other stocks like Huaye Fragrance (300886) and Kesheng Co. (300856) also showed varied capital flows, indicating differing investor sentiments across the sector [3]

Core Viewpoint - The collagen market is experiencing a downturn, with major brands like Kefu Mei and Juzhi Biotech showing declining sales and growth rates, indicating a shift from a previously booming market to a more cautious phase [1][3][5]. Market Performance - The overall performance of the collagen sector during the 2025 Double Eleven shopping festival was disappointing, with Kefu Mei's GMV on Douyin dropping to 0.5-0.75 billion yuan, down from over 1 billion yuan in the same period last year [3][4]. - Juzhi Biotech's stock price has fallen by 55.18% since reaching a peak of 85.14 HKD on May 20, 2023, reflecting the company's struggles with slowing growth and ingredient controversies [5][6]. Strategic Shifts - Major players are beginning to cross market boundaries, with Juzhi Biotech expanding into B-end business and Kefu Mei attempting to adapt to changing market dynamics [6][7]. - The market is witnessing a transition from a focus on consumer products to medical applications, as companies aim to leverage technological advancements and regulatory clarity [7][10]. Industry Trends - The industry is moving towards a more scientific and clinical approach, with companies like Huaxi Biotech and Furuida actively pursuing medical device certifications and focusing on the development of injectable collagen products [8][9][10]. - The competitive landscape is shifting from brand recognition and channel dominance to a focus on material science and clinical validation, emphasizing the importance of proving product efficacy [10][11].

Investment Rating - The report assigns an "Outperform" rating to multiple companies including Nike, Midea Group, JD Group, Haier Smart Home, Gree Electric, Anta Sports, China Duty Free, and others [1]. Core Insights - The report highlights that domestic and overseas consumer subsectors are not showing synchronized movements, with internal factors driving stock performance [4][10]. - The performance of various sectors is analyzed, indicating that the U.S. hotel sector has outperformed others, while luxury goods and overseas cosmetics have seen significant declines [10][13]. Sector Performance Summary - **U.S. Hotels**: The sector saw a weekly increase of 7.9%, driven by strong performance from Marriott and Hilton, with Marriott's RevPAR growth meeting market expectations [5][13]. - **Pet Sector**: Increased by 1.1%, with leading brands showing significant growth in GMV despite overall sales being weak [5][13]. - **Gambling Sector**: Rose by 0.7%, with Macau's GGR exceeding expectations, indicating strong future performance [5][13]. - **Retail Sector**: Experienced a slight decline of 0.3%, with China Duty Free benefiting from new tax policies [7][13]. - **Snack Sector**: Fell by 1.9%, with competitive pressures affecting performance [7][13]. - **Gold and Jewelry Sector**: Decreased by 2.5% due to tax reforms impacting profitability [7][13]. - **Overseas Sportswear**: Dropped by 2.8%, facing tariff pressures and concerns over U.S. consumer spending [7][13]. - **Luxury Goods**: Declined by 3.0%, with concerns over upcoming earnings reports affecting stock prices [7][13]. - **Domestic Cosmetics**: Fell by 3.4%, with overall performance weaker than international brands [7][13]. - **Overseas Cosmetics**: Experienced a significant drop of 11.6%, primarily due to ELF Beauty's disappointing earnings [7][13]. Valuation Analysis - Most sectors are valued below their average over the past five years, with specific PE ratios indicating potential undervaluation [8][14]. - **Overseas Sportswear**: Expected PE of 28.6, 54% of the past five-year average [14]. - **Domestic Sportswear**: Expected PE of 14.1, 74% of the past five-year average [14]. - **Gold and Jewelry**: Expected PE of 22.1, 42% of the past five-year average [14]. - **Luxury Goods**: Expected PE of 25.6, 46% of the past five-year average [14]. - **Gambling**: Expected PE of 29.1, 47% of the past five-year average [14]. - **Overseas Cosmetics**: Expected PE of 35.5, 53% of the past five-year average [14]. - **Domestic Cosmetics**: Expected PE of 27.9, 52% of the past five-year average [14]. - **Pet Sector**: Expected PE of 40.3, 55% of the past five-year average [14]. - **Snack Sector**: Expected PE of 26.8, 65% of the past five-year average [14]. - **Retail Sector**: Expected PE of 28.6, 53% of the past five-year average [14]. - **U.S. Hotels**: Expected PE of 31.4, 19% of the past five-year average [14]. - **Credit Card Sector**: Expected PE of 28.9, 55% of the past five-year average [14].

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [6][29]. Core Insights - The October CPI performance exceeded expectations, with a year-on-year increase of 0.2%, higher than the consensus forecast of -0.04%. The core CPI, excluding food and energy, rose by 1.2%, marking the highest increase since March 2024 [4][24]. - The implementation of the new duty-free policy in Hainan has led to a surge in tourism consumption, with duty-free shopping amounting to 506 million yuan from November 1 to 7, representing a year-on-year growth of 34.86% [5][27]. - Key events in the beauty care sector include Kimberly-Clark's acquisition of Kenvue, expected to complete in the second half of 2026, and Amorepacific's Q3 operating profit increasing by 41% [4][24]. Summary by Sections Market Performance - For the week of November 3 to November 7, the retail trade, social services, and beauty care sectors saw changes of +0.31%, +0.11%, and -3.10% respectively, ranking 17th, 19th, and 31st among 31 primary industries [15][17]. Key Industry Data and News - The beauty care sector is highlighted by Kimberly-Clark's acquisition of Kenvue and Amorepacific's significant profit increase. Additionally, new medical devices have received regulatory approval [4][24]. - In the travel sector, the number of domestic flights increased by 4.9% compared to 2019, with a total of approximately 101,000 flights executed in the week [5][24]. - The IP derivatives market is seeing growth, with significant sales expected from the film "Wang Wang Mountain" and new store openings in the toy sector [5][28]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Juzhibio, Marubi, Runben, Proya, Chaohongji, and Furuida within the beauty care and new consumption sectors [6][29].

Core Insights - The cosmetics sector experienced a slight decline of 0.09% on November 11, with Lafang Jiahua leading the drop [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Market Performance - Notable gainers in the cosmetics sector included: - Yusong Co., Ltd. (300132) with a closing price of 8.08, up 3.59% and a trading volume of 703,100 shares, totaling 569 million yuan [1] - Bavi Co., Ltd. (920123) with a closing price of 18.18, up 2.42% and a trading volume of 35,200 shares, totaling 63.21 million yuan [1] - Lafang Jiahua (603630) closed at 23.17, down 1.45%, with a trading volume of 50,100 shares, totaling 116 million yuan [2] - The overall net capital flow in the cosmetics sector showed a net outflow of 64.16 million yuan from main funds, while retail funds saw a net inflow of 28.82 million yuan [2][3] Capital Flow Analysis - Main funds showed significant outflows in several companies: - Jiahen Jiahua (300955) had a main fund net outflow of 15.26 million yuan, with a retail net inflow of 21.48 million yuan [3] - Lafang Jiahua (603630) experienced a main fund net outflow of 7.23 million yuan, but retail funds saw a net inflow of 9.61 million yuan [3] - Shanghai Jahwa (600315) had a main fund net inflow of 1.61 million yuan, while retail funds had a net outflow of 12.56 million yuan [3]

Core Viewpoint - The cosmetics sector experienced a notable increase of 3.13% on November 10, with Lafang Jiahua leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] - Lafang Jiahua's stock price rose by 6.14% to 23.51, with a trading volume of 96,700 shares and a transaction value of 223 million [1] - Other notable performers included: - Jiahen Jiahua: 5.57% increase, closing at 36.79 with a transaction value of 124 million [1] - Qingsong Co.: 4.56% increase, closing at 7.80 with a transaction value of 362 million [1] - Proya: 4.46% increase, closing at 73.32 with a transaction value of 759 million [1] Group 2: Fund Flow Analysis - The cosmetics sector saw a net inflow of 152 million from institutional investors, while retail investors experienced a net outflow of 179 million [1] - Key fund flows for selected companies included: - Lafang Jiahua: 22.32 million net inflow from institutional investors, with a net outflow of 11.42 million from retail investors [2] - Beitaini: 34.32 million net inflow from institutional investors, with a net outflow of 13.48 million from retail investors [2] - Shanghai Jahwa: 24.72 million net inflow from institutional investors, with a net outflow of 30.62 million from retail investors [2]

Investment Rating - The report suggests a positive investment outlook for the beauty and personal care sector, recommending a "buy" rating for high-growth companies with strong brand power and innovative product offerings [2][3]. Core Insights - The beauty and personal care sector is experiencing a slow recovery, with significant differentiation among sub-sectors. Personal care products and innovative channels continue to perform strongly, while the cosmetics sector shows signs of slowing growth due to domestic brand competition [1][2][3]. - For 2026, the overall beauty and personal care market is expected to remain stable, but further differentiation among companies is anticipated. The report emphasizes the importance of selecting high-growth targets with product and channel innovations [2][3]. Summary by Sections Overall Market Performance - In the first three quarters of 2025, the beauty and personal care sector saw revenues and net profits increase by 2.7% and 4.9% respectively, with personal care outperforming cosmetics and medical aesthetics [12][31]. - The cosmetics sector experienced a slight decline in revenue, with a 0.4% decrease year-on-year, while net profit fell by 2.3% [31][33]. Personal Care Sector - The personal care segment achieved revenues of 52 billion yuan and net profits of 5 billion yuan, reflecting a year-on-year increase of 33.7% and 5.7% respectively. The third quarter alone saw a revenue increase of 41.1% [12][16]. - Companies like Ruoyuchen reported impressive growth, with a 123% increase in revenue and a 73% increase in net profit in the third quarter [12][28]. Cosmetics Sector - The cosmetics sector's revenue for the first three quarters was 308 billion yuan, with a net profit of 30 billion yuan, showing a decline of 0.4% and 2.3% respectively. The third quarter saw a revenue drop of 0.5% but a significant profit increase of 50.8% [12][31]. - The report highlights the importance of individual company strategies and product life cycles in determining performance within the cosmetics sector [13][48]. Medical Aesthetics Sector - The medical aesthetics segment reported revenues of 75 billion yuan and net profits of 27 billion yuan, with a slight revenue decline of 0.7% but a profit increase of 14.5% year-on-year [12][52]. - The third quarter saw a revenue increase of 1.8% and a remarkable profit growth of 96.6%, although underlying performance was affected by increased competition and integration challenges [52][56]. Investment Recommendations - The report recommends focusing on high-growth companies with strong brand power, such as Ruoyuchen, Shangmei, and Maogeping, as well as companies with stable fundamentals and potential for marginal improvement like Dengkang Oral and Shanghai Jahwa [2][3]. - It also suggests monitoring companies that are expected to reach a turning point, such as Runben and Jinjian Biological, which may present investment opportunities [2][3].

Core Viewpoint - The company reported its Q3 2025 results, showing a revenue increase of 25.5% year-on-year, with a net profit growth of 2.13% [1][2]. Financial Performance - For Q1-Q3 2025, the company achieved revenue of 2.45 billion yuan, with a net profit of 240 million yuan [1]. - In Q3 alone, revenue reached 690 million yuan, reflecting a 14.3% year-on-year growth, while net profit was 69.48 million yuan, up 11.6% year-on-year [1]. - The non-recurring net profit decreased by 20% year-on-year in Q3 [1]. Segment Performance - In Q3 2025, revenue by product category was as follows: eye care (150 million yuan, +20%), skincare (310 million yuan, +42%), cleansing (70 million yuan, +23%), and beauty products (150 million yuan, -27%) [2]. - The main brand is expected to maintain good growth, while the sub-brand "Lianhuo" is under pressure [2]. - Average prices for skincare products increased due to a higher sales proportion of eye care products and a decrease in lower-priced eye care product sales [2]. Profitability Analysis - For Q1-Q3 2025, the net profit margin decreased by 2.3 percentage points to 10% [2]. - Gross margin slightly increased by 0.3 percentage points to 74.9% [2]. - The increase in sales, management, and R&D expense ratios contributed to a total expense ratio increase of 3.1 percentage points [2]. Investment Outlook - The company continues to implement a big product strategy, with its two main brands, "Marubi" and "Lianhuo," showing sustained growth [3]. - New products like "Little Gold Needle Cream" and "Little Gold Needle Mask" are expected to contribute to growth [3]. - EPS forecasts for 2025, 2026, and 2027 are 0.95, 1.12, and 1.29 yuan per share, respectively, maintaining a "buy" rating [3].